What predicts mucosal inflammation in Crohn's disease patients?

Inflammatory Bowel Diseases

Volumn 13, Issue 12, 2007, Pages 1567-1572

  Minderhoud, Itta M ^a   Samsom, Melvin ^a   Oldenburg, Bas ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Gastroenterology F02618 ^*  (Netherlands)

Author keywords

Clinical disease activity; Crohn's disease; Endoscopy; Laboratory markers; Mucosal inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALGRANULIN;

CROHN DISEASE; CROHN DISEASE ENDOSCOPIC INDEX OF SEVERITY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DUTCH INDEX; GASTROINTESTINAL ENDOSCOPY; HARVEY BRADSHAW INDEX; HUMAN; MUCOSA INFLAMMATION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RUTGEERT SCORE; SCORING SYSTEM; SIMPLE ENDOSCOPIC SCORE FOR CROHN DISEASE;

BIOLOGICAL MARKERS; CROHN DISEASE; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; SEVERITY OF ILLNESS INDEX;

EID: 38049032902     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20233     Document Type: Review

References (46)

1. Minderhoud IM, Oldenburg B, Wismeijer JA, et al. IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci. 2004;49:469-474.
2. Simren M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396.
3. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997;112:1475-1481.
4. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999; 50:667-671.
5. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
6. D'Haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-1034.
7. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
9. Hommes DW, Baert F, Van Assche G, et al. Management of recent onset Crohn's disease: a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology. 2005;128(Suppl 2):A577.
10. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
11. Naber AH, de Jong DJ. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med. 2003;61:105-110.
12. O'Morain C, Tobin A, Leen E, et al. Criteria of case definition in Crohn's disease and ulcerative colitis. Scand J Gastroenterol Suppl. 1989;170:7-11; discussion 16-19.
13. Garrett JW, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology. 1990;99: 90-96.
14. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003; 17(Suppl 2):11-17.
15. Kjeldsen J, Schaffalitzky de Muckadell OB. Assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastroenterol. 1993;28:1-9.
16. Lamers CB, Biemond I, van der Sluys Veer A, et al. Assessment of inflammatory activity in Crohn's disease. Neth J Med. 1994;45:52-54.
17. Camilleri M, Proano M. Advances in the assessment of disease activity in inflammatory bowel disease. Mayo Clin Proc. 1989;64:800-807.
18. Modigliani R, Mary JY. Reproducibility of colonoscopic findings in Crohn's disease: a prospective multicenter study of interobserver variation. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Dig Dis Sci. 1987;32:1370-1379.
19. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983-989.
20. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopie activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505-512.
21. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672.
22. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99: 956-963.
23. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
24. Working party Emea. Guideline on the development of new medicinal products for the treatment of Crohn's disease. www.emea.europa.eu/ pdfs/human/ewp/228499.pdf 2007.
25. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology. 1979;77:843-846.
26. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231-235.
27. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopie picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-818.
28. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
29. Gomes P, du Boulay C, Smith CL, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92-95.
30. van Hees PA, van Eiteren PH, van Lier HJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut. 1980;21:279-286.
31. Simonis B, Heine M, Heene DL, et al. Evaluation and validation of a Crohn's disease inflammatory activity index reflecting pattern of endoscopic severity. Scand J Gastroenterol. 1998;33:283-288.
32. Myren J, Bouchier IA, Watkinson G, et al. The OMGE multinational inflammatory bowel disease survey 1976-1986. A further report on 3175 cases. Scand J Gastroenterol Suppl. 1988;144:11-19.
33. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity - the Cape Town index. S Afr Med J. 1985;68:502-503.
34. Elliott PR, Lennard-Jones JE, Hathway N. Simple index of Crohn's disease activity. Lancet. 1980;19;1:876.
35. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96:804-810.
36. Casellas F, Alcala MJ, Prieto L, et al. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol. 2004; 99:457-461.
37. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
38. Tromm A, Tromm CD, Huppe D, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol. 1992;27:774-778.
39. Moran A, Jones A, Asquith P. Laboratory markers of colonoscopic activity in ulcerative colitis and Crohn's colitis. Scand J Gastroenterol. 1995;30:356-360.
40. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712.
41. Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
42. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437.
43. Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
44. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007; 56:453-455.
45. de Dombal FT, Softley A. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. International Organisation for the Study of Inflammatory Bowel Disease. Gut. 1987;28:474-481.
46. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology. 2004;126:1257-1269.